Additionally, these results have not been consistently replicated in other studies, including the ICT-107 Phase IIb trial evaluating the efficacy of a DC vaccine pulsed with 6 glioma-associated peptides that are commonly expressed in GBM (human epidermal growth factor (HER)2, interleukin (IL)13Rα2, TRP-2, gp100, MAGE-1, and AIM-2) in ndGBM patients. Here, ERBB2 is linked to glioblastoma.